Article Sidebar
Published:
Nov 21, 2023Keywords:
Article Details
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
AMPDR journal provides immediate open access to all content on the principle that making research freely available to the public supports a greater global exchange of knowledge. AMPDR grants usage rights to others using the open license CC-BY-NC allowing for immediate free access to the work and permitting any user to read, download, copy, distribute, print, search, or link to the full texts of articles, crawl them for indexing, pass them as data to software, or use them for any other lawful purpose.
Main Article Content
Updated mini-review of the chemistry, pharmacology and validated assays for U.S. FDA approved COVID-19 therapeutic agents
Abstract
The fish market in Wuhan, China was the epicenter of Covid-19 pandemic, brought about by the SARSCoV-2 virus, resulting in significant economic and social worldwide disruption. Although numerous drugs have been indicated for treating the viral infection and/or its symptoms, the U.S. FDA to date has granted approvals for only four therapeutic agents, namely the smallmolecules Remdesivir, Baricitinib and two monoclonal antibody combinations amlanivimab/etesevimab and casirivimab/imdevimab]. This review deals with the chemical and pharmacological aspects of these approved therapeutic agents as well as the properties of their reported marketed formulations and biological matrices. Furthermore, it presents a comparison between the cited analytical methodologies for each drug separately. A comprehensive, detailed, mini-overview of Coronavirus authorized therapeutics is also presented.
